Prescription medicine
Dextrose and heparin
Dextrose and heparin is a prescription medicine. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the dextrose and heparin FDA label on DailyMed (effective July 31, 2023, B. Braun Medical Inc.); every dextrose and heparin label on DailyMed.
Highlights of the record
FDA label of July 31, 2023; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageHeparin Sodium in 5% Dextrose Injection is indicated for: Prophylaxis and treatment of venous thrombosis and pulmonary embolism Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation Treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation) Prevention of clotting in arterial and cardiac surgery Prophylaxis and treatment of peripheral arte
Forms and strengths
- 100ml / 5 g/100ml
Injection.
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 3 since 2019 0 Class I among all firms' recalls; latest May 9, 2023
- FAERS reports
- 706 through July 30, 2026
What is dextrose and heparin used for?
From the label: indications and usageHeparin Sodium in 5% Dextrose Injection is indicated for: Prophylaxis and treatment of venous thrombosis and pulmonary embolism Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation Treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation) Prevention of clotting in arterial and cardiac surgery Prophylaxis and treatment of peripheral arterial embolism Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures. Heparin sodium is indicated for: ( 1 ) Prophylaxis and treatment of venous thrombosis and pulmonary embolism; […]
Conditions named in the indications of dextrose and heparin's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Anti-coagulant and Unfractionated Heparin.
Source: FDA drug label (Heparin Sodium in Dextrose), B. Braun Medical Inc., effective July 31, 2023 (SPL set 92a6f533-1a3d-4734-b413-d245592454e3), via openFDA; the full label on DailyMed
Is there a generic for dextrose and heparin?
No generic dextrose and heparin is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
Has dextrose and heparin been recalled?
The FDA's Enforcement Report lists 3 recalls naming dextrose and heparin since 2019: 0 Class I (the most serious), 3 Class II, 0 Class III; 0 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| May 9, 2023 | Class II | B. Braun Medical Inc | Subpotent: Low anti-factor IIa Potency. |
| March 1, 2023 | Class II | B. Braun Medical Inc | Subpotent Drug: low Anti-Factor IIa potency. |
| June 13, 2019 | Class II | B. Braun Medical Inc | Subpotent Drug: low out-of-specification results were identified for the drug anti-factor IIa potency which is intended to ensure that the potency of heparin … |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the dextrose and heparin label say about other medicines?
The dextrose and heparin label names 10 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Celecoxib | drug interactions | Drugs such as NSAIDS (including acetylsalicylic acid, ibuprofen, indomethacin, and celecoxib), dextran, phenylbutazone, thienopyridines, dipyridamole, hydroxychloroquine, glycoprotein IIv/IIa antagonists (including abciximab, eptifibatide, and tirofiban), and others that interfere with platelet-aggregation reactions … |
| Dipyridamole | drug interactions | Drugs such as NSAIDS (including acetylsalicylic acid, ibuprofen, indomethacin, and celecoxib), dextran, phenylbutazone, thienopyridines, dipyridamole, hydroxychloroquine, glycoprotein IIv/IIa antagonists (including abciximab, eptifibatide, and tirofiban), and others that interfere with platelet-aggregation reactions … |
| Eptifibatide | drug interactions | Drugs such as NSAIDS (including acetylsalicylic acid, ibuprofen, indomethacin, and celecoxib), dextran, phenylbutazone, thienopyridines, dipyridamole, hydroxychloroquine, glycoprotein IIv/IIa antagonists (including abciximab, eptifibatide, and tirofiban), and others that interfere with platelet-aggregation reactions … |
| Hydroxychloroquine | drug interactions | Drugs such as NSAIDS (including acetylsalicylic acid, ibuprofen, indomethacin, and celecoxib), dextran, phenylbutazone, thienopyridines, dipyridamole, hydroxychloroquine, glycoprotein IIv/IIa antagonists (including abciximab, eptifibatide, and tirofiban), and others that interfere with platelet-aggregation reactions … |
| Ibuprofen | drug interactions | Drugs such as NSAIDS (including acetylsalicylic acid, ibuprofen, indomethacin, and celecoxib), dextran, phenylbutazone, thienopyridines, dipyridamole, hydroxychloroquine, glycoprotein IIv/IIa antagonists (including abciximab, eptifibatide, and tirofiban), and others that interfere with platelet-aggregation reactions … |
| Indomethacin | drug interactions | Drugs such as NSAIDS (including acetylsalicylic acid, ibuprofen, indomethacin, and celecoxib), dextran, phenylbutazone, thienopyridines, dipyridamole, hydroxychloroquine, glycoprotein IIv/IIa antagonists (including abciximab, eptifibatide, and tirofiban), and others that interfere with platelet-aggregation reactions … |
| Nicotine | drug interactions | Medications that May Interfere with Heparin Digitalis, tetracyclines, nicotine, antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. |
| Nitroglycerin | drug interactions | Medications that May Interfere with Heparin Digitalis, tetracyclines, nicotine, antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. |
| Tirofiban | drug interactions | Drugs such as NSAIDS (including acetylsalicylic acid, ibuprofen, indomethacin, and celecoxib), dextran, phenylbutazone, thienopyridines, dipyridamole, hydroxychloroquine, glycoprotein IIv/IIa antagonists (including abciximab, eptifibatide, and tirofiban), and others that interfere with platelet-aggregation reactions … |
| Warfarin | drug interactions | Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained. |
Source: FDA drug label (Heparin Sodium in Dextrose), B. Braun Medical Inc., effective July 31, 2023 (SPL set 92a6f533-1a3d-4734-b413-d245592454e3), via openFDA; the full label on DailyMed
What do FAERS reports show for dextrose and heparin?
The FDA Adverse Event Reporting System holds 706 reports that list dextrose and heparin among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 132 are coded as a death and 337 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as dextrose and heparin?
2 other medicines are given the same way (intravenous) and in the same FDA class as dextrose and heparin or labeled mainly for the same use (atrial fibrillation), the same class first. Atrial fibrillation lists all 17 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Other anti-coagulants
- the pharmacologic class, with prices and generics
- Dextrose and heparin side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other